[illegible]

HUA MEDICINE
華領醫藥

[illegible]
(stock code: 2552)

VOLUNTARY ANNOUNCEMENT

(1) ACQUISITION OF 100% EQUITY INTERESTS IN THE TARGET COMPANY AND (2) ENTERING INTO OF THE PROJECT COOPERATIVE DEVELOPMENT FRAMEWORK AGREEMENT

[illegible] (**Company**, [illegible] **Group**) [illegible]

ACQUISITION OF 100% EQUITY INTERESTS IN THE TARGET COMPANY

[illegible] (**Board**) [illegible] (**Directors**) [illegible] 18 [illegible] 2022, [illegible] * (華領醫藥技術(上海)有限公司) (**Hua Shanghai**) [illegible] (**Equity Transfer Agreement**) [illegible] * (李延奎) [illegible] (**Transferors**), [illegible] 100% [illegible] * (南京盛德瑞爾醫藥科技有限公司) (**Target Company**), [illegible] (**Consideration**) [illegible] B1,025,000 (**Acquisition**). [illegible] 30 [illegible] (**Completion**). [illegible]

[illegible]

A , , , n , (, n , n , 14.07 , , G , n , L , n , S , n , S k E , n , H n K n L , (**Listing Rules**)) , A , n , n , 5%, A , n , n , n , n , n , C , 14 , L , n .

Completion is subject to the fulfilment or waiver of the conditions precedent set out in the Equity Transfer Agreement and therefore the Acquisition may or may not proceed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

COOPERATIVE PROJECT WITH TARGET COMPANY

B , , , n n , 17 , 2022, H , S n , n , C n , n , n , , , , n , S k , n , (**Framework Agreement**) , n , n , n , n , D n , n , n n , n .

INFORMATION OF THE GROUP

H , S n , n , C , S C , n , n , n , n , C n .

G , C n , n , n , n , H n n (華堂寧), , n , 2 , (2D).

INFORMATION ON THE TARGET COMPANY

C n , n , S C , n , I , n , n , n , n , A , n n , n , C n , L nk * (李延奎) (n , D L C n).

REASONS AND BENEFITS OF THE ACQUISITION AND THE PROPOSED COOPERATION

C n A , n , n , n , , n , , n , G , n , C n ' , n , n , k n n . D L C n n . D. n . D. , n k n n , S , n , 18 , k n C n ' H , n n n , S , n , n , n . D n , D L , n , , n , n , n n , n , k n , n n , D C S n , n , , n k n , n n , D F n k . , D L ' , n , n , n , n , n , n , n . In 2018, D L n , C n , k n . C n A , n n , n G , n , n , k, n , n , n , n , n , n , k n , n , n , n , n , n . A n , D L n , , n , C S n , n G , n , CE , C n n , , G , CE , D C n L , , k n n n , . D C n C S , n G , , n .

D E A F
A C C

B B
Dr. Li Chen
C E E D

S , 18 2022

A B D L C G C C L D ; D ; K k, K J L A D .